Pharming Group is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company operates in the biopharmaceutical market, primarily serving patients who suffer from rare diseases that are often overlooked by larger pharmaceutical companies. Pharming's business model revolves around the development, production, and commercialization of innovative therapies that address unmet medical needs. The company generates revenue through the sale of its proprietary products, licensing agreements, and strategic partnerships with other pharmaceutical firms. Pharming's core product is Ruconest, a recombinant human C1 esterase inhibitor used to treat acute hereditary angioedema attacks. The company is also advancing its pipeline with other promising therapies, including leniolisib for the treatment of Activated PI3K Delta Syndrome (APDS). By focusing on niche markets with high unmet needs, Pharming aims to provide sustainable solutions for patients, healthcare professionals, and stakeholders.

Keywords: biopharmaceutical, rare diseases, Ruconest, hereditary angioedema, leniolisib, APDS, innovative therapies, niche markets, sustainable solutions, patient-focused.